查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2028 年轉基因乙型肝炎疫苗市場
市場調查報告書
商品編碼
1215769

2022-2028 年轉基因乙型肝炎疫苗市場

Recombinant Hepatitis B Vaccine Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 | 商品交期: 2-3個工作天內

價格

在預測期內，全球重組乙型肝炎疫苗市場預計將以 5.6% 的複合年增長率顯著增長。 市場增長的主要驅動力是由於乙型肝炎流行的加劇，對乙型肝炎疫苗接種和生產的需求激增。 在這個行業經營的公司正專注於與其他市場參與者合作，以擴大業務並保持市場競爭力。 例如，2021 年 5 月，Dynavax Technologies Corp.與 Bavarian Nordic 就在德國銷售和分銷 HEPLISAV B [乙型肝炎疫苗（重組），佐劑]簽訂了商業化協議。 HEPLISAV B 是唯一獲得美國食品和藥物管理局 (FDA) 和歐盟委員會 (EC) 批准的成人乙型肝炎疫苗，允許在一個月內完成兩劑方案。 然而，與乙型肝炎疫苗相關的副作用預計會阻礙市場增長。

全球重組乙型肝炎疫苗市場根據類型和應用進行細分。 根據類型，市場分為 10mcg/ml 和 10mcg/0.5ml。 根據應用，市場分為新生兒/兒科和成人。

從地域上看，重組乙型肝炎疫苗市場分為北美、歐洲、亞太地區和世界其他地區。 預計在預測期內，北美將佔據最高的市場份額。 由於肝癌上升，對乙型肝炎疫苗的高需求是推動該地區市場增長的一個突出方面。 乙型肝炎疫苗被認為是第一種抗癌疫苗，因為它有助於預防肝癌，肝癌是癌症死亡的第二大原因。 美國癌症協會估計，到 2022 年，美國將診斷出約 41,260 例新病例（28,600 名男性和 12,660 名女性）和 30,520 名（20,420 名男性）原發性肝癌和肝內膽管癌患者（10,100 名女性）死亡來自這些癌症。 這將導致對重組乙型肝炎疫苗的需求增加。

內容

第 1 章報告概述

  • 當前行業分析和增長前景
  • 研究方法和工具
  • 市場細分
    • 按細分
    • 按地區

第 2 章市場概述和洞察

  • 調查範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 推薦
    • 總結

第三章競爭格局

  • 主要公司分析
    • 概覽
    • 財務分析
    • SWOT 分析
    • 近期趨勢
  • 關鍵策略分析

第四章市場細分

  • 全球重組乙型肝炎疫苗市場：按類型分類
    • 10微克/毫升
    • 10 微克/0.5 毫升
  • 重組乙型肝炎疫苗的全球應用市場
    • 新生兒/兒科
    • 成人

第五章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 世界其他地方
    • 拉丁美洲
    • 中東和非洲

第六章公司簡介

  • Bharat Biotech International Ltd.
  • CSL Ltd.
  • Dynavax Technologies Corp
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • KM Biologics（Meiji Holdings Co., Ltd.）
  • LG Chem Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt., Ltd.
  • Sinovac Biotech Ltd.
  • VBI Vaccines, Inc.
Product Code: OMR2026825

Title:Global Recombinant Hepatitis B Vaccine Market Size, Share and Trends Analysis, By Type (10mcg/ml and 10mcg/0.5ml), By Application (Newborn/ Children and Adult), Forecast Period (2022-2028).

The global recombinant hepatitis B vaccine market is anticipated to grow at a substantial CAGR of 5.6% during the forecast period. The market growth is majorly driven by the growing prevalence of hepatitis B which has surged the demand for hepatitis B vaccination and production on a large level. Companies operating in the industry are focusing on collaborating with other market players to expand their business and remain competitive in the market. For instance, in May 2021, Dynavax Technologies Corp. entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany. HEPLISAV B is the only US Food and Drug Administration (FDA) and European Commission (EC) approved hepatitis B vaccine for adults with a two-dose regimen that is completed in one month. However, the side effects associated with the hepatitis B vaccine are expected to hamper the market growth.

The global recombinant hepatitis B vaccine market is segmented based on type and application. Based on type, the market is bifurcated into 10mcg/ml and 10mcg/0.5ml. Based on application, the market is sub-segmented into newborns/children, and adults.

Geographically, the recombinant hepatitis B vaccine market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to contribute the highest share of the market during the forecast period. The high demand for hepatitis B vaccines due to increasing liver cancer is the prominent aspect driving the regional market growth. The hepatitis B vaccine is the first anti-cancer vaccine because it can help prevent liver cancer, which is the second most common cause of cancer death. As per the American Cancer Society's estimates for primary liver cancer and intrahepatic bile duct cancer in 2022, around 41,260 new cases (28,600 in men and 12,660 in women) will be diagnosed and 30,520 people (20,420 men and 10,100 women) will die of these cancers in the US. That will lead to an increase in demand for recombinant hepatitis B vaccines.

The major market players in the global recombinant hepatitis B vaccine market include Merck & Co., Inc., GlaxoSmithKline plc, Sanofi Pasteur, Dalian Hissen Bio-pharm, and Pfizer Inc., among others. The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in January 2021, Dynavax Technologies Corp. announced the final immunogenicity and interim safety results of the ongoing clinical trial evaluating HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in patients undergoing hemodialysis. As per the company, the hemodialysis trial which reinforces the existing clinical data regarding the safety and ability of HEPLISAV-B provided high rates of protection for patients undergoing hemodialysis.

Research Methodology

The market study of the global recombinant hepatitis B vaccine market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Recombinant Hepatitis B Vaccine Research and Analysis by Type
  • Global Recombinant Hepatitis B Vaccine Research and Analysis by Application

The Report Covers:

  • Comprehensive research methodology of the global recombinant hepatitis B vaccine market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global recombinant hepatitis B Vaccine market.
  • Insights about market determinants that are stimulating the global recombinant hepatitis B Vaccine market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Recombinant Hepatitis B Vaccine Market by Type
    • 4.1.1. 10mcg/ml
    • 4.1.2. 10mcg/0.5ml
  • 4.2. Global Recombinant Hepatitis B Vaccine Market by Application
    • 4.2.1. Newborn/Children
    • 4.2.2. Adult

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World
    • 5.4.1. Latin America
    • 5.4.2. Middle East & Africa

6. Company Profiles

  • 6.1. Bharat Biotech International Ltd.
  • 6.2. CSL Ltd.
  • 6.3. Dynavax Technologies Corp
  • 6.4. Emergent BioSolutions Inc.
  • 6.5. GlaxoSmithKline PLC
  • 6.6. KM Biologics (Meiji Holdings Co., Ltd.)
  • 6.7. LG Chem Ltd.
  • 6.8. Merck & Co., Inc.
  • 6.9. Novartis AG
  • 6.10. Pfizer, Inc.
  • 6.11. Sanofi S.A.
  • 6.12. Serum Institute of India Pvt., Ltd.
  • 6.13. Sinovac Biotech Ltd.
  • 6.14. VBI Vaccines, Inc.

LIST OF TABLES

  • 1. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL 10MCG/ML RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL 10MCG/0.5ML RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 5. GLOBAL RECOMBINANT HEPATITIS B VACCINE FOR NEWBORN/CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL RECOMBINANT HEPATITIS B VACCINE FOR ADULT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. NORTH AMERICAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 9. NORTH AMERICAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 10. NORTH AMERICAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 11. EUROPEAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 12. EUROPEAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 13. EUROPEAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 14. ASIA-PACIFIC RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 15. ASIA-PACIFIC RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 16. ASIA-PACIFIC RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 17. REST OF THE WORLD RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 18. REST OF THE WORLD RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 19. REST OF THE WORLD RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 2. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 3. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 4. GLOBAL 10MCG/ML RECOMBINANT HEPATITIS B VACCINE MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 5. GLOBAL 10MCG/0.5ML RECOMBINANT HEPATITIS B VACCINE MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 6. GLOBAL RECOMBINANT HEPATITIS B VACCINE FOR NEWBORN/CHILDREN MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 7. GLOBAL RECOMBINANT HEPATITIS B VACCINE FOR ADULT MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 8. US RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 9. CANADA RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 10. UK RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 11. FRANCE RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 12. GERMANY RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 13. ITALY RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 14. SPAIN RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 15. REST OF EUROPE RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. INDIA RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. CHINA RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. JAPAN RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. SOUTH KOREA RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. REST OF ASIA-PACIFIC RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)